Alzamend Neuro Inc. 2026年季度报告

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the SecuritiesExchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submittedpursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smallerreporting company or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller Accelerated filerSmaller reporting company Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). YesNo PART I – FINANCIAL INFORMATION Alzamend Neuro, Inc.Condensed Statements of Cash Flows Alzamend Neuro, Inc.Notes to Unaudited Condensed Financial Statements 1.DESCRIPTION OF BUSINESS Organization Alzamend Neuro, Inc. (the “Company” or “Alzamend”), is a clinical-stage biopharmaceutical company focused ondeveloping novel products for the treatment of Alzheimer’s disease (“Alzheimer’s”), bipolar disorder (“BD”), major depressivedisorder (“MDD”) and post-traumatic stress disorder (“PTSD”). With two current product candidates, Alzamend aims to bringtreatments or cures to market at a reasonable cost as quickly as possible. The Company’s current pipeline consists of two noveltherapeutic drug candidates: (i) a patented ionic cocrystal technology delivering a therapeutic combination of lithium, proline andsalicylate, known as AL001, through two royalty-bearing exclusive worldwide licenses from the University of South Florida Research The Company devotes substantially all its efforts towards research and development of its two product candidates and raisingcapital. The Company has not generated any product revenue to date. The Company has financed its operations to date primarilythrough debt financings and through the sale of its common stock, par value $0.0001 per share (“Common Stock”) and its preferred Reverse Stock Split On July 10, 2024, pursuant to the authorization provided by the Company’s stockholders at its annual meeting ofstockholders, the Company filed an amendment to the Certificate of Incorporation to effectuate a reverse stock split of the Company’sissued and outstanding Common Stock by a ratio of one-for-ten (the “First Reverse Split”). The First Reverse Split did not affect thenumber of authorized shares of Common Stock, preferred stock or their respective par value per share. As a result of the First Reverse On May 6, 2025, pursuant to the authorization provided by the Company’s stockholders at its annual meeting of stockholders,the Company filed an amendment to the Certificate of Incorporation to effectuate a reverse stock split of the Company’s issued andoutstanding Common Stock by a ratio of one-for-nine (the “Second Reverse Split”). The Second Reverse Split did not affect thenumber of authorized shares of Common Stock, preferred stock or their respective par value per share. As a result of the Second 2.LIQUIDITY AND GOING CONCERN The accompanying condensed financial statements have been prepared on the basis that the Company will continue as a goingconcern. As of January 31, 2026, the Company had cash of $2.7 million, working capital of $1.8 million, an accumulated deficit of$64.4 million and stockholders’ equity of $2.2 million. For the three and nine months ended January 31, 2026, the Company had net Management expects to continue to incur losses for the foreseeable future and needs to raise additional capital until it is ableto generate revenues from operations sufficient to fund its development and commercial operations during the twelve-month periodsubsequent to the issuance of the financial statements included in this Quarterly Report. These factors create substantial doubt aboutour ability to continue as a going concern. In order to continue as a going concern, the Company will need to raise additional funds.The Company plans to seek additional funding through public equity, private equity and debt financings. The terms of any additional 3.SIGNIFICANT ACCOUNTING POLICIES Basis of Presentation The accompanying condensed financial statements of the Company have been prepared in accordance with accountingprinciples generally accepted in the United States of America (“U.S. GAAP”) and the rules of the Securities and ExchangeCommission (“SEC”) applicable to interim reports of companies filing as a smaller reporting company. These condensed financialstatements should be read in conjunction with the audited financial statements and notes thereto contained in the Company’s AnnualReport on Form 10-K for the year ended April 30, 2025, filed